Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study
| العنوان: | Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study |
|---|---|
| المؤلفون: | Cynthia Turcotte, Laura MacNair, Jost Klawitter, Cristina Sempio, Erica N. Peters, Marcel O. Bonn-Miller, Mark A. Ware, Uwe Christians, M Hunter Land, Irina Mosesova |
| المصدر: | European Journal of Clinical Pharmacology |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cmax, Pilot Projects, Medical Marijuana, Pharmacology, Placebo, Cannabichromene, chemistry.chemical_compound, Double-Blind Method, Pharmacokinetics, mental disorders, parasitic diseases, medicine, Cannabidiol, Humans, Pharmacology (medical), Dronabinol, Cannabis, Dose-Response Relationship, Drug, biology, Cannabinoids, business.industry, General Medicine, Pharmacokinetics and Disposition, biology.organism_classification, chemistry, Area Under Curve, Medical cannabis, Phytocannabinoid, Δ9-tetrahydrocannabinol, business, medicine.drug |
| الوصف: | Purpose Cannabichromene (CBC) is a phytocannabinoid commonly found in cannabis, yet its acute post-dose pharmacokinetics (PK) have not been examined in humans. This is a secondary data analysis from a trial investigating Spectrum Yellow oil, an oral cannabis product used for medical purposes that contained 20 mg cannabidiol (CBD), 0.9 mg Δ9-tetrahydrocannabinol (THC), and 1.1 mg CBC, per 1 mL of oil. Methods Participants (N = 43) were randomized to one of 5 groups: 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC daily; 240 mg CBD, 10.8 mg THC, and 13.2 mg CBC daily; 360 mg CBD, 16.2 mg THC, and 19.8 mg CBC daily; 480 mg CBD, 21.6 mg THC, and 26.4 mg CBC daily; or placebo. Study medication was administered every 12 h for 7 days. Plasma CBC concentrations were analyzed by a validated two-dimensional high-performance liquid chromatography–tandem mass spectrometry assay. Results After a single dose and after the final dose, the Cmax of CBC increased by 1.3–1.8-fold for each twofold increase in dose; the tmax range was 1.6–4.3 h. Based on the ratio of administered CBD, THC, and CBC to the plasma concentration, the dose of CBD was 18 times higher than the dose of CBC, yet the AUC0–t of CBD was only 6.6–9.8-fold higher than the AUC0–t of CBC; the dose of THC was similar to the dose of CBC, yet THC was quantifiable in fewer plasma samples than was CBC. Conclusions CBC may have preferential absorption over CBD and THC when administered together. Trial Registration: Australian New Zealand Clinical Trials Registry #ACTRN12619001450101, registered 18 October 2019. |
| تدمد: | 1432-1041 0031-6970 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::653529e0ba2a61709551542ffe3e650f https://doi.org/10.1007/s00228-021-03232-8 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....653529e0ba2a61709551542ffe3e650f |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14321041 00316970 |
|---|